Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in locally advanced cervical cancer
NCT04275713Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- May 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in Cervical Cancer (CC) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Metformin dependent changes in hypoxia-related gene expression at 1 week. Started May 2020; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04275713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275713.